A Randomized Comparison of Liposomal Daunorubicin/Daunorubicin Combined with Low-Dose Cytarabine and Etoposide or High-Dose Cytarabine and Fludarabine in Induction Treatment of Pediatric AML Using MRD-Based Risk Stratification in the NOPHO-DBH AML 2012 Protocol
Author:
Barbara De Moerloose,Nira Arad-Cohen,Daniel Cheuk,Jose Maria Fernandez Navarro,Henrik Hasle,Kirsi Jahnukainen,Gertjan J.L. Kaspers,Zhanna Kovalova,Birgitte Lausen,Ulrika Norén-Nyström,Josefine Palle,Ramune Pasauliene,Cornelis Jan Pronk,Kadri Saks et al.
Copyright © 2023 The American Society of Hematology. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.